Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance disclosures regarding share ownership.
Material Changes
The filing details two specific transactions regarding share ownership:
- Employee Trust Transfer: On February 11, 2004, Abacus (GSK) Trustees Limited transferred 12,516 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Acquisition: On February 10, 2004, Director Mr. J D Coombe acquired 22 Ordinary Shares (11 via personal contribution and 11 via company matching) through the ShareReward Plan at a price of £11.79 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting statutory changes in director shareholdings.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust following the transfer of 12,516 shares.
- Confirm the updated shareholding balance for Director Mr. J D Coombe post-acquisition.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 and the ShareReward Plan for further context on these transactions.